Lobectomy Beats SBRT Survival in Early-Stage NSCLC

This article originally appeared here.
Share this content:
Lobectomy Beats SBRT Survival in Early-Stage NSCLC
Lobectomy Beats SBRT Survival in Early-Stage NSCLC

FRIDAY, Dec. 1, 2017 (HealthDay News) -- For stage I non-small-cell lung cancer, survival is better with lobectomy than stereotactic body radiation therapy (SBRT), although there is no difference for sublobar resection and SBRT, according to a study published online Nov. 29 in the Annals of Thoracic Surgery.

Alex K. Bryant, from the University of California San Diego in La Jolla, and colleagues compared cancer-specific survival among patients with biopsy-proven clinical stage I non-small-cell lung cancer receiving lobectomy, sublobar resection, or SBRT. Data were included for 4,069 patients (449 SBRT, 2,986 lobectomy, and 634 sublobar resection).

The researchers found that immediate post-procedural mortality was higher in the surgery groups than the SBRT group in unadjusted analysis. After adjustment for confounders, including preoperative pulmonary function, smoking status, comorbidity, and staging work-up procedures, the analysis considering long-term survival found higher cancer-specific mortality for SBRT than lobectomy (subdistribution hazard ratio, 1.45; 95 percent confidence interval, 1.09 to 1.94; P = 0.01), but no significant difference between SBRT and sublobar resection (subdistribution hazard ratio, 1.25; 95 percent confidence interval, 0.93 to 1.68; P = 0.15).

"Among a large cohort of early-stage lung cancer patients, we found that lobectomy had improved survival compared with SBRT, although we found no survival difference between sublobar resection and SBRT," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »